An explorative study of non-invasive ultra-weak photon emission and the anti-oxidative influence of oral zinc sulphate in light-sensitive patients with erythropoietic protoporphyria.

[erythropoietic protoporphyria]

Erythropoietic protoporphyria (EPP ) is a rare , inherited disorder of haem biosynthesis owing to deficient ferrochelatase (FECH ) and accumulation of protoporphyrin IX (PPIX ). This results in acute cutaneous photosensitivity upon light exposure with production of reactive oxygen species (ROS ) and ultra-weak photon emission (UPE ) as a by -product . We investigated if UPE evaluated the light sensitivity in EPP patients and influence of zinc treatment .Fourteen EPP patients took zinc sulphate (3 Ã— 200 Â mg /day ) during spring and summer . Using a photomultiplier (PM ), UPE was measured from the buttock skin and dorsal hand before and after solar-simulated light (SUN ) exposure . Blood samples were analysed routinely for plasma zinc , iron , ferritin , transferrin , haemoglobin , erythrocyte PPIX and Zn-PPIX .UPE in EPP patients resembled that seen in healthy individuals . Without treatment , a seasonal decrease was seen from spring to summer in four control patients . However , oral zinc treatment reduced ROS formation significantly regardless of SUN exposure . After SUN exposure , the initial burst was correlated to plasma iron and erythrocyte PPIX . During treatment , an inverse correlation was found between plasma zinc concentration and the initial burst .Measurements of UPE can be used for monitoring UVA-induced oxidative processes in vivo in the skin of EPP patients .

Diseases
Validation

Diseases presenting "oral zinc treatment" symptom

erythropoietic protoporphyria

You can validate or delete this automatically detected symptom